Physiomics PLC (PYC) · 2026-10-20
Physiomics PLC has won a £102,000 model-informed drug-development modelling contract. Finance Director Ian Bagnall said awards announced since May 2026 now exceed £970,000, compared with FY26 revenue of £941,222.
Physiomics PLC (PYC) · 2026-10-14
Physiomics PLC has won a £119,000 modelling contract, while separate heads of terms for personalised dosing technology remain non-binding and carry no agreed revenue or commercial terms.
Physiomics PLC (PYC) · 2026-10-13
Physiomics PLC grew FY26 total income 26.5% to £1,055,169, in line with the Board’s expectations, but its operating loss rose 50% to £687,254 as one-off Board-transition costs, consultant use and Biometrics investment increased spending. Revenue was £941,222, while loss after tax increased 68% to £697,034.
Physiomics plc (PYC) · 2026-09-10
Physiomics secured new contracts worth more than £205,000, lifting awards announced over a little more than four months to more than £750,000. That total equals approximately 95% of revenue reported for the whole of financial year 2024-2025.
Physiomics plc (PYC) · 2026-07-14
Physiomics says director Ian Bagnall bought 1,111,111 new ordinary shares at 0.45p each on 10 July 2026. His holding will rise to 16,111,111 shares, or about 3.55% of the issued share capital.
Physiomics plc (PYC) · 2026-07-08
Physiomics plc has secured multiple contract awards with a combined estimated value in excess of £200,000. The deals include two Biometrics extensions and a new Modelling & Simulation contract.
Physiomics plc (PYC) · 2026-07-01
Physiomics has promoted Jesse Thissen to the role of Chief Operating Officer with immediate effect. Thissen previously served as Head of Biometrics and will now oversee day-to-day operations to drive scalability and support the company's commercial growth.
Physiomics plc (PYC) · 2026-06-26
Physiomics said its largest-ever commercial pipeline, recognised revenues and near-term activity support a path towards breakeven. It also flagged cost savings that should exceed exceptional meeting-related costs, mainly next financial year.
Physiomics plc (PYC) · 2026-05-27
Physiomics has secured several new and follow-on contracts with biotechnology and oncology organisations. The projects provide near-term revenue and visibility through to the end of 2027.